|
TABLE OF CONTENTS 1 INTRODUCTION 1.1 OBJECTIVES OF THE STUDY 1.2 MARKET DEFINITION 1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY 1.4 CURRENCY 1.5 LIMITATIONS 1.6 STAKEHOLDERS 2 RESEARCH METHODOLOGY 2.1.1 RESEARCH METHODOLOGY STEPS
2.1.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY
2.1.2.1 Secondary Research
2.1.3 KEY DATA FROM SECONDARY SOURCES
2.1.3.1 Primary research
2.1.3.2 Key industry insights
2.1.4 KEY DATA FROM PRIMARY SOURCES
2.1.5 KEY INSIGHTS FROM PRIMARY SOURCES
2.1.6 MARKET SIZE ESTIMATION METHODOLOGY
2.1.7 RESEARCH DESIGN
2.1.8 MARKET DATA VALIDATION AND TRIANGULATION
2.1.9 ASSUMPTIONS FOR THE STUDY 3 EXECUTIVE SUMMARY 3.1 INTRODUCTION 3.2 CURRENT SCENARIO 3.3 FUTURE OUTLOOK 3.4 CONCLUSION 4 PREMIUM INSIGHTS 4.1 GLOBAL CANCER DIAGNOSTICS MARKET 4.2 REGIONAL SNAPSHOT OF THE CANCER DIAGNOSTICS MARKET 4.3 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY (2015 VS. 2020) 5 MARKET OVERVIEW 5.1 INTRODUCTION 5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of cancer
5.2.1.2 Technological Advancements
5.2.1.3 Initiatives undertaken by governments and global health organizations to spread awareness about cancer
5.2.1.4 Growth in the number of private diagnostic centers
5.2.1.5 Public-private partnerships to enhance the infrastructure of diagnostic imaging centers
5.2.1.6 FDA support for biomarker development
5.2.1.7 Launch of new flow cytometry reagents for diagnostics and drug discovery
5.2.2 RESTRAINTS
5.2.2.1 High capital investments & low benefit-cost ratio for biomarkers
5.2.2.2 Shortage of helium
5.2.2.3 High cost of diagnostic imaging systems affecting their rate of adoption in emerging markets
5.2.2.4 Risk of high radiation exposure likely to limit the usage of CT scanners
5.2.2.5 Dearth of skilled and experienced personnel
5.2.3 OPPORTUNITIES
5.2.3.1 Personalized medicine
5.2.3.2 Development of mass cytometry and the combination of cell-and bead-based flow cytometry technologies
5.2.3.3 Companion Diagnostics
5.2.3.4 Improving healthcare infrastructure in emerging markets
5.2.3.5 Miniaturized and technologically advanced devices
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory guidelines
5.2.4.2 Hospital budget cuts a key challenge to market players
5.2.4.3 Increasing adoption of refurbished diagnostic imaging systems 6 GLOBAL CANCER DIAGNOSTICS MARKET, BY APPLICATION 6.1 INTRODUCTION
6.1.1 BREAST CANCER
6.1.2 LUNG CANCER
6.1.3 COLORECTAL CANCER
6.1.4 MELANOMA
6.1.5 OTHER CANCERS 7 GLOBAL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 7.1 INTRODUCTION 7.2 PLATFORM-BASED DIAGNOSTICS
7.2.1 POLYMERASE CHAIN REACTION (PCR)
7.2.2 IN SITU HYBRIDIZATION (ISH)
7.2.3 IMMUNOHISTOCHEMISTRY (IHC)
7.2.4 NEXT-GENERATION SEQUENCING (NGS)
7.2.5 MICROARRAYS
7.2.6 FLOW CYTOMETRY
7.2.7 OTHER TECHNOLOGIES 7.3 INSTRUMENT-BASED
7.3.1 DIAGNOSTIC IMAGING
7.3.1.1 Magnetic resonance imaging (MRI)
7.3.1.2 Computed tomography (CT)
7.3.1.3 Positron emission tomography (PET)
7.3.1.3.1 Standalone positron emission tomography
7.3.1.3.2 Hybrid positron emission tomography
7.3.1.4 Mammography
7.3.1.5 Ultrasound
7.3.2 BIOPSIES 8 CANCER DIAGNOSTICS MARKET, BY REGION 8.1 INTRODUCTION 8.2 NORTH AMERICA
8.2.1 U.S.
8.2.1.1 GOVERNMENT INITIATIVES
8.2.1.2 INCREASE IN CANCER INCIDENCE
8.2.2 CANADA
8.2.2.1 HIGH INCIDENCE OF CANCER
8.2.2.2 GOVERNMENT FUNDING 8.3 EUROPE
8.3.1 FUNDING FOR CANCER DIAGNOSTICS RESEARCH
8.3.2 EU-5 (U.K., GERMANY, FRANCE, ITALY, SPAIN)
8.3.2.1 STRONG GOVERNMENT SUPPORT
8.3.2.2 RESEARCH COLLABORATIONS
8.3.2.3 INCREASE IN DIAGNOSTIC IMAGING CENTERS
8.3.2.4 RISING PUBLIC AND PRIVATE INVESTMENTS
8.3.3 REST OF EUROPE (ROE)
8.3.3.1 AGING POPULATION
8.3.3.2 CONFERENCES BOOSTING AWARENESS
8.3.3.3 GOVERNMENT INVESTMENTS IN RUSSIA 8.4 ASIA
8.4.1 CHINA
8.4.1.1 EXPANSION OF INTERNATIONAL PLAYERS
8.4.1.2 AGING POPULATION AND INCREASING CANCER INCIDENCE
8.4.2 JAPAN
8.4.2.1 AGING POPULATION AND HIGH HEALTHCARE EXPENDITURE IN JAPAN
8.4.3 INDIA
8.4.3.1 INCREASING FOCUS OF INTERNATIONAL PLAYERS ON INDIA
8.4.4 REST OF ASIA
8.4.4.1 PRESENCE OF INTERNATIONAL PLAYERS BOOSTING MARKET GROWTH 8.5 REST OF THE WORLD (ROW)
8.5.1 GOVERNMENT INITIATIVES BOOSTING DEMAND FOR CANCER DIAGNOSTICS
8.5.2 AGING POPULATION, PRESENCE OF INTERNATIONAL PLAYERS
8.5.3 INCREASE IN CANCER INCIDENCES AND RISING GOVERNMENT EXPENDITURE
8.5.4 GOVERNMENT INITIATIVES TO IMPROVE HEALTHCARE INFRASTRUCTURE 9 COMPETITIVE LANDSCAPE 9.1 MARKET SHARE ANALYSIS 9.2 COMPETITIVE LANDSCAPE: OVERVIEW 9.3 COMPETITIVE SITUATION AND TRENDS
9.3.1 COLLABORATIONS/AGREEMENTS/PARTNERSHIPS/ALLIANCES
9.3.2 NEW PRODUCT LAUNCHES
9.3.3 ACQUISITIONS
9.3.4 EXPANSION
9.3.5 OTHERS 10 COMPANY PROFILES 10.1 INTRODUCTION 10.3 BECTON, DICKINSON AND COMPANY
10.3.1 BUSINESS OVERVIEW
10.3.2 PRODUCT PORTFOLIO
10.3.3 KEY STRATEGY
10.3.4 RECENT DEVELOPMENTS 10.4 GE HEALTHCARE (A SUBSIDIARY OF GENERAL ELECTRIC COMPANY)
10.4.1 BUSINESS OVERVIEW
10.4.2 PRODUCT PORTFOLIO
10.4.3 KEY STRATEGY
10.4.4 RECENT DEVELOPMENTS 10.5 ABBOTT LABORATORIES
10.5.1 BUSINESS OVERVIEW
10.5.2 PRODUCT PORTFOLIO
10.5.3 KEY STRATEGY
10.5.4 RECENT DEVELOPMENTS 10.6 ROCHE HOLDING AG
10.6.1 BUSINESS OVERVIEW
10.6.2 PRODUCT PORTFOLIO
10.6.3 KEY STRATEGY
10.6.4 RECENT DEVELOPMENTS 10.7 THERMO FISHER SCIENTIFIC, INC.
10.7.1 BUSINESS OVERVIEW
10.7.2 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
10.7.3 PRODUCT PORTFOLIO
10.7.4 KEY STRATEGY
10.7.5 RECENT DEVELOPMENTS 10.8 AGILENT TECHNOLOGIES, INC.
10.8.1 BUSINESS OVERVIEW
10.8.2 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
10.8.3 PRODUCT PORTFOLIO
10.8.4 KEY STRATEGY
10.8.5 RECENT DEVELOPMENTS 10.9 ILLUMINA, INC.
10.9.1 BUSINESS OVERVIEW
10.9.2 PRODUCT PORTFOLIO
10.9.3 KEY STRATEGY
10.9.4 RECENT DEVELOPMENTS 10.10 SIEMENS HEALTHCARE
10.10.1 BUSINESS OVERVIEW
10.10.2 PRODUCT PORTFOLIO
10.10.3 KEY STRATEGY
10.10.4 RECENT DEVELOPMENTS 10.11 C.R. BARD, INC.
10.11.1 BUSINESS OVERVIEW
10.11.2 PRODUCT PORTFOLIO
10.11.3 KEY STRATEGY
10.11.4 RECENT DEVELOPMENTS 11 APPENDIX 11.1 DISCUSSION GUIDE 11.2 COMPANY DEVELOPMENTS (2012-2015)
11.2.1 QIAGEN N.V.
11.2.2 BECTON, DICKINSON AND COMPANY
11.2.3 GE HEALTHCARE
11.2.4 ABBOTT LABORATORIES
11.2.5 ROCHE HOLDING AG
11.2.6 THERMO FISHER SCIENTIFIC, INC.
11.2.7 AGILENT TECHNOLOGIES, INC.
11.2.8 ILLUMINA, INC.
11.2.9 SIEMENS HEALTHCARE 11.3 AVAILABLE CUSTOMIZATIONS 11.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 11.5 RELATED REPORTS
LIST OF TABLES
TABLE 1 RISING PREVALENCE OF CANCER IS DRIVING THE GROWTH OF THE CANCER DIAGNOSTICS MARKET
TABLE 2 HIGH CAPITAL INVESTMENT RESTRAINING THE GROWTH OF CANCER DIAGNOSTICS MARKET
TABLE 3 EMERGING MARKETS PRESENT AN ARRAY OF OPPORTUNITIES FOR THE GROWTH OF THE CANCER DIAGNOSTICS MARKET
TABLE 4 STRINGENT REGULATORY GUIDELINES ARE A MAJOR CHALLENGE IN THE CANCER DIAGNOSTICS MARKET
TABLE 5 GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2013–2020 ($MILLION)
TABLE 6 CANCER DIAGNOSTICS MARKET SIZE FOR BREAST CANCER, BY REGION, 2013–2020 ($MILLION)
TABLE 7 CANCER DIAGNOSTICS MARKET SIZE FOR LUNG CANCER, BY REGION, 2013–2020 ($MILLION)
TABLE 8 CANCER DIAGNOSTICS MARKET SIZE FOR COLORECTAL CANCER, BY REGION, 2013–2020 ($MILLION)
TABLE 9 CANCER DIAGNOSTICS MARKET SIZE FOR MELANOMA, BY REGION, 2013–2020 ($MILLION)
TABLE 10 CANCER DIAGNOSTICS MARKET SIZE FOR OTHER CANCERS, BY REGION, 2013–2020 ($MILLION)
TABLE 11 GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2013–2020 ($MILLION)
TABLE 12 GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2013–2020 ($MILLION)
TABLE 13 CANCER DIAGNOSTICS MARKET SIZE FOR PLATFORM-BASED DIAGNOSTICS, BY REGION, 2013–2020 ($MILLION)
TABLE 14 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR PCR, BY REGION, 2013–2020 ($MILLION)
TABLE 15 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR PCR, BY APPLICATION, 2013–2020 ($MILLION)
TABLE 16 CANCER DIAGNOSTICS MARKET SIZE FOR IN SITU HYBRIDIZATION, BY REGION, 2013-2020 ($MILLION)
TABLE 17 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR IN SITU HYBRIDIZATION, BY APPLICATION, 2013–2020 ($MILLION)
TABLE 18 CANCER DIAGNOSTICS MARKET SIZE FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2013–2020 ($MILLION)
TABLE 19 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR IMMUNOHISTOCHEMISTRY, BY APPLICATION, 2013–2020 ($MILLION)
TABLE 20 CANCER DIAGNOSTICS MARKET SIZE FOR NGS, BY REGION, 2013–2020 ($MILLION)
TABLE 21 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR NGS, BY APPLICATION, 2013–2020 ($MILLION)
TABLE 22 CANCER DIAGNOSTICS MARKET SIZE FOR MICROARRAYS, BY REGION, 2013–2020 ($MILLION)
TABLE 23 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR MICROARRAYS, BY APPLICATION, 2013–2020 ($MILLION)
TABLE 24 CANCER DIAGNOSTICS MARKET SIZE FOR FLOW CYTOMETRY, BY REGION, 2013–2020 ($MILLION)
TABLE 25 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR FLOW CYTOMETRY, BY APPLICATION, 2013–2020 ($MILLION)
TABLE 26 CANCER DIAGNOSTICS MARKET SIZE FOR OTHER TECHNOLOGIES, BY REGION, 2013–2020 ($MILLION)
TABLE 27 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR OTHER TECHNOLOGIES, BY APPLICATION, 2013–2020 ($MILLION)
TABLE 28 GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2013–2020 ($MILLION)
TABLE 29 CANCER DIAGNOSTICS MARKET SIZE FOR DIAGNOSTIC IMAGING, BY PRODUCT, 2013–2020 ($MILLION)
TABLE 30 CANCER DIAGNOSTICS MARKET SIZE FOR DIAGNOSTIC IMAGING, BY REGION, 2013–2020 ($MILLION)
TABLE 31 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR IMAGING, BY APPLICATION, 2013–2020 ($MILLION)
TABLE 32 CANCER DIAGNOSTICS MARKET SIZE FOR MRI, BY REGION, 2013–2020 ($MILLION)
TABLE 33 CANCER DIAGNOSTICS MARKET SIZE FOR CT, BY REGION, 2013–2020 ($MILLION)
TABLE 34 CANCER DIAGNOSTICS MARKET SIZE FOR PET, BY PRODUCT, 2013–2020 ($MILLION)
TABLE 35 CANCER DIAGNOSTICS MARKET SIZE FOR PET, BY REGION, 2013–2020 ($MILLION)
TABLE 36 CANCER DIAGNOSTICS MARKET SIZE FOR STANDALONE PET, BY REGION, 2013–2020 ($MILLION)
TABLE 37 CANCER DIAGNOSTICS MARKET SIZE FOR HYBRID PET, BY REGION, 2013–2020 ($MILLION)
TABLE 38 CANCER DIAGNOSTICS MARKET SIZE FOR MAMMOGRAPHY, BY REGION, 2013–2020 ($MILLION)
TABLE 39 CANCER DIAGNOSTICS MARKET SIZE FOR ULTRASOUND, BY REGION, 2013–2020 ($MILLION)
TABLE 40 CANCER DIAGNOSTICS MARKET SIZE FOR BIOPSY, BY REGION, 2013–2020 ($MILLION)
TABLE 41 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR BIOPSY, BY APPLICATION, 2013–2020 ($MILLION)
TABLE 42 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2013—2020 ($MILLION)
TABLE 43 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 44 NORTH AMERICA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 45 NORTH AMERICA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 46 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2013—2020 ($MILLION)
TABLE 47 U.S.: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 48 U.S.: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 49 U.S.: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 50 CANADA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 51 CANADA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 52 CANADA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 53 EUROPE: CANCER DIAGNOSTICS MARKET, BY REGION, 2013—2020 ($MILLION)
TABLE 54 EUROPE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 55 EUROPE: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 56 EUROPE: CANCER DIAGNOSTICS INSTRUMENT MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 57 EUROPE: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2013—2020 ($MILLION)
TABLE 58 EU-5: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 59 EU-5: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 60 EU-5: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 61 ROE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 62 ROE: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 63 ROE: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 64 ASIA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2013—2020 ($MILLION)
TABLE 65 ASIA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 66 ASIA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 67 ASIA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 68 ASIA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2013—2020 ($MILLION)
TABLE 69 CHINA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 70 CHINA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 71 CHINA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 72 JAPAN: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 73 JAPAN: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 74 JAPAN: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 75 INDIA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 76 INDIA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 77 INDIA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 78 ROA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 79 ROA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 80 ROA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 81 ROW: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 82 ROW: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 83 ROW: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION)
TABLE 84 ROW: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2013—2020 ($MILLION)
TABLE 85 COLLABORATIONS/AGREEMENTS/PARTNERSHIPS/ALLIANCES, 2012-2015
TABLE 86 NEW PRODUCT LAUNCHES, 2012–2015
TABLE 87 ACQUISITIONS, 2012–2015
TABLE 88 EXPANSIONS, 2012–2015
TABLE 89 OTHER STRATEGIES, 2012–2015
LIST OF FIGURES
FIGURE 1 CANCER DIAGNOSTICS MARKET SEGMENTATION
FIGURE 2 GLOBAL CANCER DIAGNOSTICS MARKET : RESEARCH METHODOLOGY STEPS
FIGURE 3 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 PLATFORM-BASED DIAGNOSTICS TO WITNESS HIGHEST CAGR OF 24.8% FROM 2015 TO 2020
FIGURE 8 GLOBAL PLATFORM-BASED CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2015–2020
FIGURE 9 GLOBAL CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY
FIGURE 10 LARGEST AND FASTEST-GROWING CANCER DIAGNOSTIC APPLICATIONS, 2015-2020
FIGURE 11 CANCER DIAGNOSTICS MARKET LIKELY TO GROW AT A CAGR OF 12.9% IN THE FORECAST PERIOD
FIGURE 12 CANCER DIAGNOSTICS MARKET, BY REGION AND APPLICATION: NORTH AMERICA WILL DOMINATE THE CANCER DIAGNOSTICS MARKET IN 2015
FIGURE 13 ASIA TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
FIGURE 14 PLATFORM-BASED TECHNOLOGY LIKELY TO GAIN SIGNIFICANT MARKET SHARE BY 2020
FIGURE 15 CANCER DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
FIGURE 16 MARKET GROWTH WILL BE DRIVEN BY RISING INCIDENCE & PREVALENCE OF BREAST AND LUNG CANCERS
FIGURE 17 LUNG CANCER APPLICATION IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 18 NGS, A GROUND-BREAKING TECHNOLOGY IN CANCER DIAGNOSIS
FIGURE 19 ULTRASOUND ACCOUNTED FOR THE LARGEST SHARE OF THE CANCER DIAGNOSTICS MARKET FOR IMAGING
FIGURE 20 GLOBAL NGS MARKET (FOR CANCER DIAGNOSTICS) SHARE ANALYSIS, BY KEY PLAYER, 2014
FIGURE 21 GLOBAL MICROARRAYS MARKET (FOR CANCER DIAGNOSTICS) SHARE ANALYSIS, BY KEY PLAYER, 2014
FIGURE 22 GLOBAL FLOW CYTOMETRY (FOR CANCER DIAGNOSTICS) MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014
FIGURE 23 GLOBAL MRI IMAGING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014
FIGURE 24 GLOBAL CT IMAGING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014
FIGURE 25 GLOBAL PET IMAGING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014
FIGURE 26 GLOBAL ULTRASOUND IMAGING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014
FIGURE 27 AGILENT TECHNOLOGIES AND QIAGEN WERE THE MOST AGGRESSIVE PLAYERS
FIGURE 28 NEW PRODUCT LAUNCHES WAS THE KEY GROWTH STRATEGY FOR MARKET PLAYERS
FIGURE 29 BATTLE FOR MARKET SHARE: COLLABORATIONS/AGREEMENTS/ PARTNERSHIPS/ ALLIANCES WERE KEY STRATEGIES
FIGURE 30 GEOGRAPHICAL REVENUE MIX OF KEY PLAYERS IN THE MARKET
FIGURE 31 QIAGEN N.V.: COMPANY SNAPSHOT
FIGURE 32 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
FIGURE 33 GE HEALTHCARE: COMPANY SNAPSHOT
FIGURE 34 ABBOTT: COMPANY SNAPSHOT
FIGURE 35 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT
FIGURE 37 SIEMENS: COMPANY SNAPSHOT
FIGURE 38 C.R. BARD, INC.: COMPANY SNAPSHOT
|
현재위치 : 
